Completed PHASE2 INTERVENTIONAL NCT00002908

Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

PHASE II CLINICAL EVALUATION OF BRYOSTATIN 1 IN PATIENTS WITH RELAPSED NON-HODGKIN'S LYMPHOMA AND CLL

Sponsor: Barbara Ann Karmanos Cancer Institute

Interventions bryostatin 1 vincristine sulfate

Updated 5 times since 2017 Last updated: Apr 3, 2013 Started: Dec 31, 1996 Primary completion: Feb 29, 2000 Completion: Nov 30, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Leukemia and Lymphoma, this trial is completed. The trial is conducted by Barbara Ann Karmanos Cancer Institute and has accumulated 5 data snapshots since 1996. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Dec 1996

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Data source: Barbara Ann Karmanos Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Detroit, United States